U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H12O3
Molecular Weight 228.2433
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of RESVERATROL

SMILES

OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1

InChI

InChIKey=LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+

HIDE SMILES / InChI

Molecular Formula C14H12O3
Molecular Weight 228.2433
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Resveratrol, a natural non-flavonoid polyphenol, exhibits a wide range of beneficial properties as an anticancer agent, a platelet anti-aggregation agent, and an antioxidant, as well as its anti-aging, anti-inflammatory, antiallergenic. This compound is in phase III clinical trials in combination with carboxymethyl-β-glucan for improving nasal symptoms in children with pollen-induced allergic rhinitis. Also in phase III clinical trial in the treatment of painful knee osteoarthritis and in type 2 diabetic patients. It has been demonstrated that resveratrol may prevent type 2 diabetic by targeting Sirtuin type 1 (SIRT1), indicating that SIRT1 may be a novel therapeutic target for diabetes prevention.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96EB6
Gene ID: 23411.0
Gene Symbol: SIRT1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1274 ng/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
689 ng/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
1272 ng/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1296 ng/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3558 ng × h/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
1966 ng × h/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
4025 ng × h/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3800 ng × h/mL
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.5 h
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
2.2 h
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.1 h
2000 mg 2 times / day multiple, oral
dose: 2000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: QUERCETIN
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1.7%
RESVERATROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Disc. AE: Abnormal liver function tests...
Other AEs: Upper respiratory tract infection NOS, Urinary tract infection NOS...
AEs leading to
discontinuation/dose reduction:
Abnormal liver function tests (7%)
Other AEs:
Upper respiratory tract infection NOS (36%)
Urinary tract infection NOS (7%)
Headache (21%)
Fatigue (14%)
Loose stools (86%)
Diarrhea (grade 1-3, 71%)
Abdominal pain (71%)
Nausea (36%)
Bloating (7%)
Flatulence (13%)
Constipation (7%)
Dyspepsia (7%)
creatine kinase (14%)
Microalbuminuria (21%)
Skin rash (29%)
Edema lower limb (7%)
Sources:
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Abdominal pain, Diarrhea...
Other AEs:
Abdominal pain (grade 1, 30%)
Diarrhea (grade 1-3, 70%)
Flatulence (grade 1, 20%)
Nausea (grade 1, 30%)
Chest pain (grade 1, 10%)
Dizziness (grade 1, 10%)
Dry mouth (grade 1, 10%)
Red eye (grade 1, 10%)
Urine color abnormal (grade 1, 10%)
Sources:
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Other AEs: Albumin increased, Blood phosphate increased...
Other AEs:
Albumin increased (grade 1, 10%)
Blood phosphate increased (grade 1, 20%)
Glucose increased (grade 1, 10%)
Carbon dioxide low (grade 1, 20%)
Lactate dehydrogenase increased (grade 1, 10%)
Blood lactate dehydrogenase decreased (grade 1, 10%)
Eosinophil count increased (grade 1, 10%)
Chloride increased (grade 1, 10%)
Sources:
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: FED
Sources:
Disc. AE: Skin rash, Constipation...
Other AEs: Diarrhea, Allergic reaction...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 3, 6%)
Constipation (grade 2, 3%)
Other AEs:
Diarrhea (grade 2, 6%)
Allergic reaction (grade 2, 3%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Flatulence 13%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Fatigue 14%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
creatine kinase 14%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Headache 21%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Microalbuminuria 21%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Skin rash 29%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Nausea 36%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Upper respiratory tract infection NOS 36%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Bloating 7%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Constipation 7%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Dyspepsia 7%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Edema lower limb 7%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Urinary tract infection NOS 7%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Abnormal liver function tests 7%
Disc. AE
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Abdominal pain 71%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Loose stools 86%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Diarrhea grade 1-3, 71%
5 g 2 times / day multiple, oral
Highest studied dose
Dose: 5 g, 2 times / day
Route: oral
Route: multiple
Dose: 5 g, 2 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: LOW-FAT
Sources:
Chest pain grade 1, 10%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dizziness grade 1, 10%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Dry mouth grade 1, 10%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Red eye grade 1, 10%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Urine color abnormal grade 1, 10%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Flatulence grade 1, 20%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Abdominal pain grade 1, 30%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Nausea grade 1, 30%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Diarrhea grade 1-3, 70%
5 g 1 times / day multiple, oral
Highest studied dose
Dose: 5 g, 1 times / day
Route: oral
Route: multiple
Dose: 5 g, 1 times / day
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Albumin increased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Blood lactate dehydrogenase decreased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Chloride increased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Eosinophil count increased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Glucose increased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Lactate dehydrogenase increased grade 1, 10%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Blood phosphate increased grade 1, 20%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Carbon dioxide low grade 1, 20%
5 g single, oral
Highest studied dose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Allergic reaction grade 2, 3%
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: FED
Sources:
Constipation grade 2, 3%
Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: FED
Sources:
Diarrhea grade 2, 6%
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: FED
Sources:
Skin rash grade 3, 6%
Disc. AE
1 g 1 times / day multiple, oral
Studied dose
Dose: 1 g, 1 times / day
Route: oral
Route: multiple
Dose: 1 g, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: F
Food Status: FED
Sources:
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
no [IC50 >50 uM]
weak [IC50 11.6 uM]
weak [IC50 150 uM]
weak [IC50 34.8 uM]
weak [IC50 35.2 uM]
weak [IC50 40 uM]
weak [IC50 >25 uM]
weak [IC50 >50 uM]
weak
weak (biomarker study)
Comment: A weak induction of CYP1A2 was shown in vivo after 4 weeks of 1 g of resveratrol per day in healthy volunteers by measuring the ratio between caffeine and the metabo-lite, paraxanthine.
yes [IC50 1.4 uM]
yes [IC50 11.6 uM]
yes [IC50 2.3 uM]
yes (biomarker study)
Comment: Resveratrol ingestion of 1 g per day for 4 weeks decreased human CYP2C9 activity.
yes [IC50 8.3 uM]
yes [IC50 9.1 uM]
yes [IC50 9.57 uM]
yes [IC50 9.8 uM]
yes (biomarker study)
Comment: Data in humans showed a decrease of CYP2D6 activity after 4 weeks of 1 g of resveratrol per day
yes
yes
yes
yes
yes
yes
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin.
1998 Dec 11
Cancer chemopreventive activity of resveratrol.
1999
Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages.
1999 Apr 15
Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials.
1999 Aug
Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
1999 Aug 19
Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol.
1999 Feb
Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects.
1999 May 14
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions.
1999 Nov 26
Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity.
1999 Oct
Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol.
1999 Oct
Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity.
1999 Oct 1
24R,25-(OH)(2)D(3) mediates its membrane receptor-dependent effects on protein kinase C and alkaline phosphatase via phospholipase A(2) and cyclooxygenase-1 but not cyclooxygenase-2 in growth plate chondrocytes.
2000 Mar
Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol.
2000 Oct
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta.
2000 Oct
Role of heme oxygenase-1 in the regulation of manganese superoxide dismutase gene expression in oxidatively-challenged astroglia.
2000 Oct
Effects of 1alpha,25-(OH)(2)D(3) on rat growth zone chondrocytes are mediated via cyclooxygenase-1 and phospholipase A(2).
2001
Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells.
2001 Apr 1
The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human cyp1a1 expression.
2001 Aug
Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase.
2001 Feb 15
Do wine polyphenols modulate p53 gene expression in human cancer cell lines?
2001 Jul
Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways.
2001 Jul
Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice.
2001 Jun
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
2001 Jun 1
Short heterodimer partner (SHP) orphan nuclear receptor inhibits the transcriptional activity of aryl hydrocarbon receptor (AHR)/AHR nuclear translocator (ARNT).
2001 Jun 1
Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells.
2001 Jun 15
Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
2001 Mar
Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts.
2001 Nov
Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice.
2002 Jun
Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants.
2002 Mar 1
Flavonoid effects relevant to cancer.
2002 Nov
Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats.
2002 Oct 11
Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray.
2003 Apr
Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals.
2003 Apr 1
Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens.
2003 Apr 30
Resveratrol induces apoptosis in human esophageal carcinoma cells.
2003 Mar
Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells.
2003 Mar
Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes.
2003 May
Patents

Sample Use Guides

Seasonal Allergic Rhinitis: 2 sprays per nostril 3 times a day for a period of two months knee osteoarthritis: resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
Route of Administration: Other
The insulinoma cell line clone 1E (INS-1E) was treated with palmitic acid (PA). PA suppressed the expression of SIRT1 in a dose- and time-dependent manner. In PA-induced INS-1E cells, it was demonstrated that 10 µM resveratrol modulated the expression of PGC-1α and FOXO3a via SIRT1 and regulated the expression of mitochondrial biogenesis-associated, lipid metabolism-associated and β-cells-associated proteins.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:27:00 GMT 2025
Edited
by admin
on Mon Mar 31 18:27:00 GMT 2025
Record UNII
Q369O8926L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIA 6-512
Preferred Name English
RESVERATROL
HSDB   INCI   MART.   MI   VANDF   WHO-DD  
INCI  
Official Name English
Resveratrol [WHO-DD]
Common Name English
CA 1201
Common Name English
RESVERATROL(E)-FORM
Common Name English
RESVIDA
Common Name English
5-((1E)-2-(4-HYDROXYPHENYL)ETHENYL)-1,3-BENZENEDIOL
Systematic Name English
TRANS-RESVERATROL [USP-RS]
Common Name English
BIOFORT
Common Name English
BIA-6-512
Code English
NSC-327430
Code English
RESVERATROL [MART.]
Common Name English
(E)-RESVERATROL
Common Name English
(E)-5-(P-HYDROXYSTYRYL)RESORCINOL
Common Name English
SRT 501M
Common Name English
TRANS-RESVERATROL
Common Name English
CUSPIDATIN
Common Name English
RESVERATROL P 5
Common Name English
Jotrol
Brand Name English
MELINJO RESVERATROL 20
Common Name English
POLYGONIN
Common Name English
RESVERATROL [HSDB]
Common Name English
RESVERATROL [VANDF]
Common Name English
5-((E)-2-(4-HYDROXYPHENYL)-ETHENYL) BENZENE-1,3 DIOL
Systematic Name English
RESVERATROL [MI]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/16/1827
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
DSLD 438 (Number of products:1077)
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
FDA ORPHAN DRUG 597817
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
NCI_THESAURUS C54630
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
FDA ORPHAN DRUG 241707
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
NCI_THESAURUS C275
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1602105
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
GRAS Notification (GRN No.)
224
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
LACTMED
Resveratrol
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
PUBCHEM
445154
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
NSC
327430
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
EVMPD
SUB32889
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID4031980
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
NCI_THESAURUS
C1215
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
CHEBI
45713
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
CAS
501-36-0
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
HSDB
7571
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
RXCUI
1000492
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY RxNorm
MESH
C059514
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
SMS_ID
100000126143
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
FDA UNII
Q369O8926L
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
DRUG BANK
DB02709
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
WIKIPEDIA
RESVERATROL
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
DAILYMED
Q369O8926L
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
MERCK INDEX
m9549
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY Merck Index
CHEBI
27881
Created by admin on Mon Mar 31 18:27:00 GMT 2025 , Edited by admin on Mon Mar 31 18:27:00 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Representative of PDE4
TRANSPORTER -> INHIBITOR
inhibited MTX efflux transport in MDR1-MDCK and MRP2-MDCK cellmonolayers, suggesting that the target of drug interaction wasMDR1 andMRP2 in the intestine duringthe absorption process.
TRANSPORTER -> INHIBITOR
inhibited MTX efflux transport in MDR1-MDCK and MRP2-MDCK cellmonolayers, suggesting that the target of drug interaction wasMDR1 andMRP2 in the intestine duringthe absorption process.
PARENT -> CONSTITUENT ALWAYS PRESENT
Stilbene was determined by means of of a newly developed rapid, sensitive, and accurate HPLC-DAD method.
METABOLIC ENZYME -> SUBSTRATE
ACTIVE CONSTITUENT ALWAYS PRESENT
METABOLIC ENZYME -> INHIBITOR
6?-hydroxylation of testosterone
IC50
TARGET -> ACTIVATOR
Resveratrol activates deacetylase activity while inhibiting desuccinylase activity.
TRANSPORTER -> INHIBITOR
MTX uptake was markedly inhibited by Res in rat kidney slicesand hOAT1/3-HEK293 cell, indicating that OAT1 and OAT3 were involved in the drug interaction in the kidney
TRANSPORTER -> INHIBITOR
MTX uptake was markedly inhibited by Res in rat kidney slicesand hOAT1/3-HEK293 cell, indicating that OAT1 and OAT3 were involved in the drug interaction in the kidney
TARGET -> INHIBITOR
TARGET -> INHIBITOR
CONSTITUENT ALWAYS PRESENT -> PARENT
METABOLIC ENZYME -> INHIBITOR
resveratrol inactivated CYP3A4 in a time- and NADPH-dependent manner, with rate (kinact) and affinity (equilibrium dissociation constant for enzyme-inhibitor complex; KI) of 0.2?min?1 and 20 ?M, respectively
TIME-DEPENDENT INHIBITION
Ki
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT
Activity against BACE-1 with Ki value of 5.4 x 10-6M and IC50 of 1.5 x 10-5M.
Related Record Type Details
METABOLITE -> PARENT
Some patients formed this metabolite presumably due to microbiome differences.
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY